Clinical Trials
4 trialsNCT06890884 2026-05-22
MK-2140-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06015880 2026-05-13
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT03274492 2026-05-08
POLARIX
Hoffmann-La Roche
Phase 3 Completed
NCT05283720 2026-05-06
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting